Chronic losartan administration reduces mortality and preserves cardiac but not skeletal muscle function in dystrophic mice

PLoS ONE

Volumn 6, Issue 6, 2011, Pages

  Bish, Lawrence T ^a   Yarchoan, Mark ^a   Sleeper, Meg M ^b   Gazzara, Jeffrey A ^a   Morine, Kevin J ^a   Acosta, Pedro ^a   Barton, Elisabeth R ^c   Sweeney, H Lee ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY OF PENNSYLVANIA SCHOOL OF DENTAL MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYPROLINE; LOSARTAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARDIOMYOPATHY; CARDIOVASCULAR FUNCTION; CONTROLLED STUDY; DIAPHRAGM; DISEASE ASSOCIATION; DISEASE COURSE; DUCHENNE MUSCULAR DYSTROPHY; FUNCTIONAL MORPHOLOGY; HEART MUSCLE FIBROSIS; LONG TERM CARE; MALE; MORTALITY; MOUSE; MUSCLE FUNCTION; MUSCLE MASS; MYOFIBROSIS; NONHUMAN; PHENOTYPE; RISK REDUCTION; STAIN; TRANSTHORACIC ECHOCARDIOGRAPHY; TRICHROME STAIN; ANIMAL; ANIMAL MUSCULAR DYSTROPHY; DRUG EFFECT; ECHOGRAPHY; FIBROSIS; HEART; HEART FUNCTION TEST; HEART MUSCLE; HEART MUSCLE CONDUCTION SYSTEM; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; SKELETAL MUSCLE; SURVIVAL; X CHROMOSOME LINKED MUSCULAR DYSTROPHIC MOUSE;

ANIMALIA; MUS;

ANIMALS; FIBROSIS; HEART; HEART CONDUCTION SYSTEM; HEART FUNCTION TESTS; LOSARTAN; MALE; MICE; MICE, INBRED MDX; MUSCLE, SKELETAL; MUSCULAR DYSTROPHY, ANIMAL; MYOCARDIUM; SURVIVAL ANALYSIS;

EID: 79959442500     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0020856     Document Type: Article

References (26)

1. Hoffman EP, Brown RH Jr, Kunkel LM, (1987) Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell 51: 919-928.
2. Baxter P, (2006) Treatment of the heart in Duchenne muscular dystrophy. Dev Med Child Neurol 48: 163.
3. Nowak KJ, Davies KE, (2004) Duchenne muscular dystrophy and dystrophin: pathogenesis and opportunities for treatment. EMBO Rep 5: 872-876.
4. Leask A, Abraham DJ, (2004) TGF-beta signaling and the fibrotic response. FASEB J 18: 816-827.
5. Cohn RD, van Erp C, Habashi JP, Soleimani AA, Klein EC, et al. (2007) Angiotensin II type 1 receptor blockade attenuates TGF-beta-induced failure of muscle regeneration in multiple myopathic states. Nat Med 13: 204-210.
6. Passerini L, Bernasconi P, Baggi F, Confalonieri P, Cozzi F, et al. (2002) Fibrogenic cytokines and extent of fibrosis in muscle of dogs with X-linked Golden Retriever muscular dystrophy. Neuromuscul Disord 12: 828-835.
7. Campistol JM, Inigo P, Jimenez W, Lario S, Clesca PH, et al. (1999) Losartan decreases plasma levels of TGF-beta1 in transplant patients with chronic allograft nephropathy. Kidney Int 56: 714-719.
8. Esmatjes E, Flores L, Inigo P, Lario S, Ruilope LM, et al. (2001) Effect of losartan on TGF-beta1 and urinary albumin excretion in patients with Type 2 diabetes mellitus and microalbuminuria. Nephrol Dial Transplant 16 (Suppl 1): 90-93.
9. Kuehn BM, (2007) Studies point way to new therapeutic prospects for muscular dystrophy. Jama 298: 1385-1386.
10. Wagner KR, (2008) Approaching a new age in Duchenne muscular dystrophy treatment. Neurotherapeutics 5: 583-591.
11. Silcocks PB, Munro JF, Steeds RP, Channer KS, (1997) Prognostic implications of qualitative assessment of left ventricular function compared to simple routine quantitative echocardiography. Heart 78: 237-242.
12. Barton ER, (2006) Impact of sarcoglycan complex on mechanical signal transduction in murine skeletal muscle. Am J Physiol Cell Physiol 290: C411-419.
13. Pickering JG, Boughner DR, (1990) Fibrosis in the transplanted heart and its relation to donor ischemic time. Assessment with polarized light microscopy and digital image analysis. Circulation 81: 949-958.
14. Van Erp C, Loch D, Laws N, Trebbin A, Hoey AJ, (2010) Timeline of cardiac dystrophy in 3-18-month-old mdx mice. Muscle Nerve 42: 504-513.
15. Bostick B, Yue Y, Long C, Marschalk N, Fine DM, et al. (2009) Cardiac expression of a mini-dystrophin that normalizes skeletal muscle force only partially restores heart function in aged mdx mice. Mol Ther 17: 253-261.
16. Mouisel E, Vignaud A, Hourde C, Butler-Browne G, Ferry A, (2010) Muscle weakness and atrophy are associated with decreased regenerative capacity and changes in mTOR signaling in skeletal muscles of venerable (18-24-month-old) dystrophic mdx mice. Muscle Nerve 41: 809-818.
17. Gregorevic P, Blankinship MJ, Allen JM, Chamberlain JS, (2008) Systemic microdystrophin gene delivery improves skeletal muscle structure and function in old dystrophic mdx mice. Mol Ther 16: 657-664.
18. Spurney CF, Sali A, Guerron AD, Iantorno M, Yu Q, et al. (2011) Losartan decreases cardiac muscle fibrosis and improves cardiac function in dystrophin-deficient mdx mice. J Cardiovasc Pharmacol Ther 16: 87-95.
19. Teekakirikul P, Eminaga S, Toka O, Alcalai R, Wang L, et al. (2010) Cardiac fibrosis in mice with hypertrophic cardiomyopathy is mediated by non-myocyte proliferation and requires TGF-beta. J Clin Invest 120: 3520-3529.
20. Gunther S, Baba HA, Hauptmann S, Holzhausen HJ, Grossmann C, et al. (2010) Losartan reduces mortality in a genetic model of heart failure. Naunyn Schmiedebergs Arch Pharmacol 382: 265-278.
21. Lim DS, Lutucuta S, Bachireddy P, Youker K, Evans A, et al. (2001) Angiotensin II blockade reverses myocardial fibrosis in a transgenic mouse model of human hypertrophic cardiomyopathy. Circulation 103: 789-791.
22. Ferreira JC, Moreira JB, Campos JC, Pereira MG, Mattos KC, et al. (2011) Angiotensin receptor blockade improves the net balance of cardiac Ca(2+) handling-related proteins in sympathetic hyperactivity-induced heart failure. Life Sci 88: 578-585.
23. Colussi C, Berni R, Rosati J, Straino S, Vitale S, et al. (2010) The histone deacetylase inhibitor suberoylanilide hydroxamic acid reduces cardiac arrhythmias in dystrophic mice. Cardiovasc Res 87: 73-82.
24. Dupont E, Ko Y, Rothery S, Coppen SR, Baghai M, et al. (2001) The gap-junctional protein connexin40 is elevated in patients susceptible to postoperative atrial fibrillation. Circulation 103: 842-849.
25. Vinge LE, Raake PW, Koch WJ, (2008) Gene therapy in heart failure. Circ Res 102: 1458-1470.
26. Kaye DM, Hoshijima M, Chien KR, (2008) Reversing advanced heart failure by targeting Ca2+ cycling. Annu Rev Med 59: 13-28.